XLON
AMS
Market cap809mUSD
Jul 09, Last price
279.00GBP
1D
0.18%
1Q
32.86%
Jan 2017
25.82%
IPO
3,221.43%
Name
Advanced Medical Solutions Group PLC
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Advanced Medical Solutions Group plc (AMS), along with its subsidiaries, specializes in the innovation, production, and worldwide distribution of advanced medical solutions. Its primary markets include wound treatment, surgical procedures, and wound closure, with a significant presence across the United Kingdom, Germany, France, wider Europe, the United States, and other international regions. The company's operations are structured into two main divisions: Surgical and Woundcare. The Surgical segment provides a comprehensive range of specialized products. These include topical tissue adhesives for sealing and closing wounds, offered under the LiquiBand brand; sutures and collagen-derived materials for surgical and dental applications, marketed as RESORBA; various collagen products; the LiquiBand Fix8 laparoscopic device designed for internally securing hernia meshes; and internal sealants available under the Seal-G and Seal-G MIST brands. Conversely, the Woundcare segment focuses on a broad spectrum of sophisticated wound management technologies. Its offerings comprise alginates, medical foams, films, fibers, hydrogels, antimicrobial dressings, and hydrocolloids, alongside a dedicated line of wound care products under the ActivHeal brand. Established in 1991, Advanced Medical Solutions Group plc maintains its corporate headquarters in Winsford, United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||